Abstract:BACKGROUND: Liver cholestasis can be a life-threatening complication during home parenteral nutrition and may lead to combined liver-intestinal transplantation.OBJECTIVE: To assess the prevalence of home parenteral nutrition-related liver disease and its contributing factors in patients with permanent intestinal failure.DESIGN: Prospective cohort study.SETTING: Two approved home parenteral nutrition centers.PATIENTS: 90 patients with permanent intestinal failure who were receiving home parenteral nutrition were enrolled from 1985 to 1996.INTERVENTION: Clinical, biological, endoscopic, and ultrasonographic follow-up. Histologic examination of the liver was done in 57 patients (112 liver biopsies).MEASUREMENTS: The Kaplan-Meier method was used to determine the actuarial occurrence of chronic cholestasis and complicated home parenteral nutrition-related liver disease (bilirubin level > or =60 micromol/L [3.5 mg/dL], factor V level < or =50%, portal hypertension, encephalopathy, ascites, gastrointestinal bleeding, or histologically proven extensive fibrosis or cirrhosis). Contributing factors were assessed by using univariate and multivariate (Cox model) analysis.RESULTS: 58 patients (65%) developed chronic cholestasis after a median of 6 months (range, 3 to 132 months), and 37 (41.5%) developed complicated home parenteral nutrition-related liver disease after a median of 17 months (range, 2 to 155 months). Of these patients, 17 showed extensive fibrosis after 26 months (range, 2 to 148 months) and 5 had cirrhosis after 37 months (range, 26 to 77 months). The prevalence of complicated home parenteral nutrition-related liver disease was 26%+/-9% at 2 years and 50%+/-13% at 6 years. Six patients died of liver disease (22% of all deaths). In multivariate analysis, chronic cholestasis was significantly associated with a parenteral nutrition-independent risk for liver disease, a bowel remnant shorter than 50 cm in length, and a parenteral lipid intake of 1 g/kg of body weight per day or more (omega-6-rich long-chain triglycerides), whereas complicated home parenteral nutrition-related liver disease was significantly associated with chronic cholestasis and lipid parenteral intake of 1 g/kg per day or more.CONCLUSION: The prevalence of complicated home parenteral nutrition-related liver disease increased with longer duration of parenteral nutrition. This condition was one of the main causes of death in patients with permanent intestinal failure. Parenteral intake of omega-6-rich long-chain triglycerides lipid emulsion consisting of less than 1 g/kg per day is recommended in these patients.

Reversal of intestinal failure associated liver disease fibrosis in a patient receiving long term home parenteral nutrition

The Gut Microbiome and Intestinal Failure-Associated Liver Disease

Lactobacillus Johnsonii Attenuates Liver Steatosis and Bile Acid Dysregulation in Parenteral Nutrition-Fed Rats.

Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations

Exploring the long-term risk factors associated with intestinal failure-associated liver disease in pediatric and adult patients: The role of lipid injectable emulsions in the development of liver disease

Clinical approach to the management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN

Use of Mixed-Oil Fat Emulsion to Improve Intestinal Failure–Associated Liver Disease in Long-Term Home Parenteral Nutrition: A Case Report

Parenteral nutrition-associated liver injury: clinical relevance and mechanistic insights

Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure

Intravenous lipid emulsions and liver function in adult chronic intestinal failure patients: Results after 5 y of home parenteral nutrition

The role of Src in solid and hematologic malignancies

Hepatic Fibrosis Persists and Progresses Despite Biochemical Improvement in Children Treated With Intravenous Fish Oil Emulsion

Natural bioactive compounds-The promising candidates for the treatment of intestinal failure-associated liver disease

Intestinal Failure-Associated Liver Disease and Growth Pre- and Post-Transition to a Composite Lipid Emulsion

Clinical application of fish-oil intravenous lipid emulsion in adult home parenteral nutrition patients

Intestinal failure-associated liver disease in the neonatal ICU: what we know and where we're going

Inflammation drives pathogenesis of early intestinal failure-associated liver disease

Prevalence of Liver Disease and Contributing Factors in Patients Receiving Home Parenteral Nutrition for Permanent Intestinal Failure

Trends in liver profile and nutrition outcomes in children undergoing intestinal rehabilitation using a mixed lipid injectable emulsion

Parenteral fish oil lipid emulsion use in adults: a case series and review from an intestinal failure referral center